Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
GMABMedia Release
COPENHAGEN, Denmark; August 26, 2025
Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7:45 AM EDT (1:45 PM CEST) on September 9, 2025. A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-presentations.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
GMABCOPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-directed, TOPO1-inhibitor antibody-drug conjugate (ADC), for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing re
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
GMABCOPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide (R2) versus R2 alone for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study met its dual primary endpoints of overall response rate (ORR, p-value < 0.0001) and progression-free survival (PFS, HR 0.21, p-valu
Genmab Announces New Data From Cohort B2 Of Phase 1/2 RAINFOL-01 Trial Evaluating Rina-S, TOPO1-Inhibitor Antibody-Drug Conjugate
GMABGenmab To Present First Clinical Results For Rina-S In Advanced Endometrial Cancer And Long-Term Follow-Up Data For Epcoritamab In R/R DLBCL At ASCO 2025, Highlighting Progress In Late-Stage Oncology Pipeline
GMABGenmab To Present 14 Abstracts Evaluating Epcoritamab As Monotherapy And In Combination Across Disease Settings In Patients With DLBCL And FL At EHA Congress 2025
GMABGenmab Q1 EPADS $0.31 Beats $0.23 Estimate, Sales $715.00M Miss $748.58M Estimate
GMABReported Earlier, Genmab To Submit sBLA To FDA for Epcoritamab Plus R2 In Relapsed/Refractory Follicular Lymphoma Following Positive Phase 3 Data
GMABGenmab Announces Net Sales Of DARZALEX (daratumumab) For Q1: Says Net sales Of DARZALEX Totaled $3.237B, Co Received Royalties On Worldwide Net Sales From Johnson & Johnson
GMABWhat Analysts Are Saying About Genmab Stock
GMABHC Wainwright & Co. Reiterates Buy on Genmab, Lowers Price Target to $37
GMABJapanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
GMABGenmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.
Genmab Announces That The Japan Ministry Of Health, Labour And Welfare Has Approved TIVDAK For The Treatment Of Advanced Or Recurrent Cervical Cancer That Has Progressed On Or After Cancer Chemotherapy. TIVDAK Is the First And Only Antibody-Drug Conjugate
GMABGenmab Announces Updated Data From Cohort B1 Of The Phase 1/2 RAINFOL-01 Study Of Rinatabart Sesutecan; Showed That With A Median On-Study Follow-Up Of 48 Weeks, Led To A Confirmed Objective Response Rate Of 55.6% And Median Duration Of Response Was Not R
GMABBreaking Down Genmab: 4 Analysts Share Their Views
GMABTruist Securities Maintains Buy on Genmab, Lowers Price Target to $45
GMABWilliam Blair Upgrades Genmab to Outperform
GMABCORRECTION: Genmab shares are trading lower after Johnson & Johnson decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize HexaBody-CD38. Genmab will not pursue further clinical development.
GMABGenmab Says Johnson & Johnson Decision Regarding HexaBody-CD38 Does Not Impact 2025 Financial Guidance
GMABGenmab Announces Johnson & Johnson Has Decided That It Will Not Exercise Its Option To Receive A Worldwide License To Develop, Manufacture And Commercialize HexaBody-CD38; Genmab Will Not Pursue Further Clinical Development
GMABGenmab Announces Japan Approval Of EPKINLY For Treating Relapsed/Refractory Follicular And Large B-Cell Lymphomas; First Subcutaneous T-Cell Engaging Bispecific Antibody Approved In Japan, U.S., EU For Dual Indication
GMABLeerink Partners Upgrades Genmab to Outperform, Announces $27 Price Target
GMABGenmab Expects Its 2025 Operating Profit To Be In Range Of $0.9B-$1.4B; Expects Its 2025 Revenue To Be In Range Of $3.3B-$3.7B, Compared To $3.1B In 2024; Sees 2025 Operating Expenses To Be In Range Of $2.1B-$2.2B; Anticipates Its 2025 Operating Expenses
GMABGenmab Reports 29% Revenue Growth For First Nine Months Of 2024 To DKK 15.1B, Updates Full-Year Financial Guidance With Expected Revenue Of DKK 21.1B To DKK 21.7B And Gross Profit Of DKK 20.2B To DKK 20.8B
GMABGenmab To Showcase Strength And Breadth Of Comprehensive Epcoritamab-bysp Development Program At The 2024 ASH Annual Meeting
GMABPreview: Genmab's Earnings
GMABWhat 9 Analyst Ratings Have To Say About Genmab
GMABHC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
GMABCowen & Co. Initiates Coverage On Genmab with Market Perform Rating, Announces Price Target of $38
GMAB